Briacell Therapeutics Corp. Fact Sheet

September 2018 BriaCell Corporate Office - Canada : Suite 300 – Bellevue Centre, 235 -15th Street, West Vancouver, BC V7T 2X1, Tel: 604-921-1810 BriaCell US Corporate Office : 820 Heinz Avenue, Berkeley, CA, 94710, Tel: 1-888-485-6340 ; http: /briacell.com/ For further information , please contact: Email: info@BriaCell.com BriaCell is a clinical stage immuno-oncology focused biotechnology company developing the first off-the-shelf personalized immunotherapy for cancer. The company is conducting a Phase IIa clinical trial for its lead product candidate, Bria-IMT™ , in advanced breast cancer along with the co-development of BriaDX™ , its companion diagnostic test. Additionally, there is an FDA approved combination study of Bria-IMT™ with pembrolizumab or ipilimumab for patients with advanced breast cancer previously treated with Bria-IMT™. Moreover, BriaCell is developing Bria-OTS™ , the first “off-the-shelf” personalized treatment for advanced stage Breast Cancer. BriaCell's small molecule program consists of novel, selective protein kinase C delta inhibitors which have shown activity in pre-clinical models of several cancers and fibrotic diseases. Investment Highlights  Developing the First Off-the-Shelf Personalized Immunotherapy  Targeting Advanced Breast Cancer  Unmet medical need (42,000 women died in U.S. during 2017 from Advanced Breast Cancer)  $1 Bil - $5 Bil market opportunity depending on patient treatment stage  Impressive results in 2 completed proof-of-concept human clinical trials:  Rapid Response Rate; Successful retreatment following a relapse  Excellent Safety Profile (only ~20% with injection site rash)  Bria-IMT™ has completed Phase I clinical trial with encouraging data  Ongoing Phase IIa trial with positive confirmatory clinical data and a combination therapy study with Keytruda® or Yervoy®  Bria-OTS™ is currently in development along with BriaDX™, its companion diagnostic test  Ability to match and treat ~90% of the advanced breast cancer population with Off-the-Shelf personalized immunotherapy cell lines  Experienced Management has been involved in over 10 drug approvals  Significant Near-Term News-flow BriaCell Leadership Team William V. Williams, MD President, Chief Executive Officer Gadi Levin, CA, MBA Chief Financial Officer Markus Lacher, PhD Senior Director, R&D Farrah Dean, MSc, MBA Manager, Corp. Development Board of Directors Saeid Babaei, PhD, MBA , Chairman President & CEO, AbCelex Technologies Rahoul Sharan, CA , Director President, KJN Management Ltd. Martin Schmieg, CPA , Director General Manager, Soar Ventures Charles Wiseman, MD , Director & Co-Founder; Clinical Professor of Medicine, Division of Medical Oncology, Keck-USC School of Medicine William V. Williams, MD , Director President & CEO, BriaCell OTCQB: BCTXF TSX-V: BCT

RkJQdWJsaXNoZXIy NDMyMDk=